This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Treatment and prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In the Classical Jewish and Mediterranean variety and the endemic African variety, Kaposi's sarcoma (KS) is an indolent condition with no significant reduction in life expectancy.

The majority of cases diagnosed in the UK today present with advanced disease and previously undiagnosed HIV infection (1)

  • local therapies including cryotherapy, radiotherapy and topical treatments are effective for treating patients with early skin lesions
  • many patients presenting with KS will respond to highly active antiretroviral therapy (HAART) and require no other intervention
  • unsightly lesions on the face or other exposed areas may be excised or may respond well to short courses of radiotherapy. More extensive limb involvement responds well to wide-field irradiation
  • when the disease is progressing rapidly in spite of HAART or when there is visceral involvement, systemic treatment with cytotoxic chemotherapy is indicated.

Reference:

  1. NICE (February 2006).CSG Improving Outcomes for People with Skin Tumours including Melanoma: The Manual

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.